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Abstract: Glyceryl trinitrate (GTN) is one of the earliest known treatments for angina with a fas-
cinating history that bridges three centuries. However, despite its central role in the nitric oxide
(NO) story as a NO-donating compound, establishing the precise mechanism of how GTN exerts its
medicinal benefit has proven to be far more difficult. This review brings together the explosive and
vasodilatory nature of this three-carbon molecule while providing an update on the likely in vivo
pathways through which GTN, and the rest of the organic nitrate family, release NO, nitrite, or a
combination of both, while also trying to explain nitrate tolerance. Over the last 20 years the alcohol
detoxification enzyme, aldehyde dehydrogenase (ALDH), has undoubtedly emerged as the front
runner to explaining GTN’s bioactivation. This is best illustrated by reduced GTN efficacy in subjects
carrying the single point mutation (Glu504Lys) in ALDH, which is also responsible for alcohol
intolerance, as characterized by flushing. While these findings are significant for anyone following
the GTN story, they appear particularly relevant for healthcare professionals, and especially so, if
administering GTN to patients as an emergency treatment. In short, although the GTN puzzle has
not been fully solved, clinical study data continue to cement the importance of ALDH, as uncovered
in 2002, as a key GTN activator.
Keywords: glyceryl trinitrate; NO-donors; organic nitrates; nitric oxide; aldehyde dehydrogenase;
nitrate tolerance
1. Introduction
That nitric oxide (NO) has many roles in animal and plant physiology had lain undis-
covered for many thousands of years was partly because it is such a small molecule and
one that has a very short lifetime in a biological milieu. The discovery that it is a significant
intermediate in the vitally important process of vascular smooth muscle relaxation was
announced in 1987 in two seminal papers [1,2]. The discovery of a biological role for NO
was greeted with some surprise and a little incredulity but the evidence is compelling. This
evidence involved a demonstration that an aqueous solution of NO behaved biologically
the same, with regard to smooth muscle relaxation, as the endothelium-derived relaxing
factor (EDRF) discovered by Furchgott and Zawadzki in 1980 [3]. Glyceryl trinitrate (GTN)
was used as a benchmark muscle relaxant with which NO and the EDRF were compared.
Murad had established that GTN is a relaxant for vascular smooth muscle ex vivo, but the
mechanism had not been studied in detail [4]. However, once the role of NO as a relaxant
had been established, the presence of so many nitro-groups in GTN suggested its action
might involve the formation of NO. However, there are chemical difficulties with this
suggestion, although it appears so obvious. The transformation of nitrogen in a nitro-group
into nitrogen in NO involves a 3-electron reduction, something unlikely to occur in one
step. It is more probable there are two steps, one 2-electon step and a second one that
is a 1-electron process [5]. The general chemistry and history of GTN and how it might
generate NO in vivo are topics covered in this review.
There are two important factors to be borne in mind in any study of GTN. Firstly, GTN
is a high explosive and produces oxides of nitrogen when it is detonated, but this is no
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guide to the mechanism of NO release under physiological conditions. Secondly, GTN does
not spontaneously generate NO in the way, for example, that some S-nitroso compounds
do (Equation (1)) [6]. Instead, such compounds could be muscle relaxants in vivo because
of an accelerated release of NO under physiological conditions.
2RSNO
∆,hv or Cu+−−−−−−−−⇀↽ − RSSR + 2NO (1)
2. Invention of Glyceryl Trinitrate
The first synthesis of GTN is credited to the Italian chemist Ascanio Sobrero (1812–1888),
a native of Piedmont. After studying chemistry in France and Germany he returned, in 1843,
to Italy to take up a post at the Technical School in Torino. In Paris he had witnessed the
successful nitration of cotton by the use of concentrated nitric acid, but when he tried this
procedure on glycerine (1,2,3-trihydroxypropane) the product was oxalic acid. Clearly nitric
acid had acted solely as an oxidising agent. However, use of a mixture of concentrated nitric
and sulphuric acids gave Sobrero a different product, an oil that reminded him of olive oil
and he called it pyroglycerine. Subsequent work showed that it was 1,2,3-trinitroxypropane
or glyceryl trinitrate (GTN). It is generally referred to as GTN, although nitroglycerine
is also commonly used. Sobrero found its most conspicuous property was its explosive
action and he delayed making an announcement of his discovery because of the hazards in
manipulation of the material. He was badly injured in one experiment.
3. Dynamite
Some years after its discovery GTN was taken up by the Swedish explosives en-
trepreneur Alfred Nobel [7]. He incorporated it into a diatomaceous earth (kieselguhr)
to produce dynamite that was much safer to handle than GTN itself, although Alfred’s
brother was killed in an accident during the development of the explosive. Dynamite is
used extensively in civil engineering and Nobel deeply regretted its use in warfare. Such
was the commercial success of dynamite that it contributed substantially to Nobel’s fortune
from which he established the Nobel prizes. Although Nobel always gave credit to Sobrero
for the invention of GTN, the latter felt he deserved greater recognition.
4. Biological Action of GTN
As was common practice at that time, Sobrero tasted the product he had made and the
result was a severe headache that lasted several hours. Other members of the laboratory
tried the same experiment with the same result. The reason for this effect was not obvious
at the time, but it was not seen as an observation of value to humankind. However, it was
of interest to one group of doctors, those who practised homeopathic medicine. During the
19th century homeopathic medicine was popular, although its scientific basis was slight
and it is now largely discredited. One essential principle of homeopathic medicine is similia
similibus curantur, ‘like cures like’. If GTN causes headaches then it must also be a cure
for them.
As a prelude to its use in homeopathic medicine, it was subjected to a process of
Prüfung or ‘proving’ by prominent homeopathic believers in which its biological properties
were examined in some detail so that, when it came to be used clinically in regular medicine,
some of the relevant safety considerations had already been examined. This is one of the
few beneficial crossovers from homeopathic to allopathic prescribing.
5. GTN as a Muscle Relaxant
Angina pectoris is a medical condition typical of old people, but especially in elderly
gentlemen of unseemly lifestyle. The conspicuous symptoms are breathlessness and an
intense chest pain when the victim is hurried or emotionally distressed. The physician and
physiologist Lauder Brunton found that he could relieve the pain of angina by venesection,
although it did not cure the condition. This suggests that the condition could be caused by
increased arterial tension, so he sought an agent that would lower blood pressure rapidly
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and reversibly. For this he chose inhalation of the recently invented compound amyl nitrite.
More correctly, it is isoamyl nitrite, but the distinction is rarely made. That amyl nitrite
did just that was discovered by a number of scientists, including Guthrie, Richardson, and
Gamgee [8,9]. The last of these was a colleague of Brunton in Edinburgh. Clinical trials
showed that it did, indeed, relieve the symptoms of angina rather well.
Amyl nitrite is not an ideal drug although it was regularly and frequently prescribed
for the relief of angina and other conditions. Firstly, it is very volatile, and you can think
you have a phial of amyl nitrite for emergency use when you have not. Secondly, the effect
wears off very quickly. So, the search began for an alternative that did not have these
shortcomings. It should be noted that no-one, at this time, seemed surprised that amyl
nitrite had the effect it did and it would take another 100 years before any explanation
was offered.
Amyl nitrite is still with us but with a somewhat different role. It was sold in the UK
and the USA under the street name of ‘poppers’. When inhaled it not only relieves the
symptoms of angina but also enlarges arteries to the brain and makes the recipient light
headed. This, among some of the young, was equated with happiness. You can still buy it
on the Internet under the name ‘Liquid Gold’, a rather extravagant name for a nostrum
giving only a transient thrill, but such is the folly of humankind.
6. The Coming of GTN
Since its invention by Sobrero, it had been known that GTN was biologically active
and it was soon established that its effect was due to a lowering of arterial tension, but
the effect was variable and nonreproducible. The side effect of a severe headache was a
barrier to its use in clinical medicine. Murrell, then a doctor at Westminster Hospital in
London, decided to investigate the situation systematically in order to clarify matters. He
experimented on himself at first, but later used a primitive sphygmometer to compare the
effect of amyl nitrite and GTN on a patient’s pulse. With GTN the onset of pulse increase
is slow but the effect is more sustained. Additionally, people varied in their response to
the same dose of GTN and this may account for some of the early confusion. Headaches
were avoided by keeping the dosage to a minimum, although for some sufferers a slight
headache was an inevitable consequence of the use of GTN. By 1892 GTN had become
the treatment of choice for angina relief and was included in the British Pharmacopoeia
as a stock remedy. It is still in use today, over 100 years later. A liquid is not the most
convenient form for a drug, and it has been suggested that it could be incorporated into
a chocolate which be eaten either in one mouthful or nibbled when relief is required [10].
This suggestion does not seem to have been taken up.
The continued use of GTN in the treatment of angina indicates that it is a successful
drug. For a long period, the mechanism of action remained a mystery with little speculation
about it. With the discovery of a role for NO in the cardiovascular system, it seemed obvious
that NO must be part of the mechanism of action. This is almost certainly correct but the
remainder of the mechanism, the conversion of a 20 atom molecule like GTN into a diatomic
molecule, is not a simple one-step process. More recent research has shed some light on
this matter.
7. The GTN Conundrum
Despite GTN usage by physicians since the late nineteenth century and still today
in sublingual, transdermal, and slow intravenous infusions to routinely treat chest pain,
heart failure, and heart attacks, its precise mechanism of action has remained something
of a mystery. This conundrum extends beyond GTN and encompasses the entire organic
nitrate family, including isosorbide mononitrate (ISMN), isosorbide dinitrate (ISDM), and
pentaerythrityl tetranitrate (PETN) (Figure 1). As one of the most common classes of NO-
donating compounds, organic nitrates, on first inspection at least, appear rather obvious
in terms of their mode of action, with downstream events replicating those seen by other
exogenous NO-donating species, where soluble guanylate cyclase (sGC) activation is
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followed by cyclic GMP-mediated relaxation. However, in similar fashion to the EDRF
puzzle, which eluded us all over so many years before the Nobel Prize winning discovery
of NO as the key biological messenger, by comparison, GTN has continued as a treatment
and something of a tease over the past 150 years. Well beyond the 30th anniversary of the
crucial NO discovery work [1–4,11,12], the crux of the GTN debate has rested on trying to
understand its in vivo activity in terms of whether it primarily releases nitrite through a
two-electron reduction, or nitric oxide by a three-electron reduction process, and in either
case, how exactly is this achieved?
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7 times greater than for 1,3-GDN [5,13–16]. Such observations demonstrate regioselectiv-
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9. Non-Enzymatic Reactions
For non-enzymatic GTN reactions, especially with thiols [18,19], the products are far
clearer, with both 1,2 and 1,3-GDN generated [13], along with a stoichiometric amount of
thionitrate (Equation (2)), which can then react with further thiolate or thiol, depending
on the local pH, to generate nitrite (Equation (3)) or nitrous acid (Equation (4)), respec-
tively [20–23]. In support of this pathway, the ISMN metabolite of ISDM has also been
achieved in a model reaction with 2-mercaptoethanol at concentrations mimicking those
seen by an enzyme [21]. The subsequent generation of dinitrogen trioxide by the slow
bimolecular conversion of nitrous acid (Equation (5)) is questionable even under acidic
conditions [24], but if this is achieved, free NO can be generated by homolytic cleavage of
N2O3 (Equation (6)) or via nitrosation of thiol to yield S-nitrosothiols (Equation (7)), which
can then homolytically cleave to release NO in the presence of heat, light, or copper, as seen
previously by Equation (1) [25]. These reactions can therefore justify the formation of either
nitrite or free NO. The reduction of nitrite to NO can also be achieved by ascorbate [26,27],
but the mechanism involving RSNOs is far more appealing from the point of view of NO
storage, to justify a more prolonged supply of NO in vivo. However, it has been reported
that bioactivation of nitrite by non-enzymatic pathways, such as these, only becomes
significant at millimolar concentrations of nitrite [13,28]. Reactions between cysteine and
organic nitrates have also been shown to be highly dependent on temperature [29]. In
addition, non-enzymatic reactions between GTN and either hemoglobin and myoglobin
should also be considered as viable alternatives [30].
GTN + RSH −−⇀↽− RSNO2 + GDN (2)
RSNO2 + RS− −−⇀↽− RSSR + NO2− (3)
RSNO2 + RSH −−⇀↽− RSSR + HNO2 (4)
2HNO2 −−⇀↽− N2O3 + H2O (5)
N2O3 −−⇀↽− NO + NO2 (6)
N2O3 + RSH −−⇀↽− RSNO + HNO2 (7)
10. Mechanistic Evidence from Observations Outside of the Lab
To ascertain how GTN and other organic nitrates function in vivo, there is a need to
return to the very beginning of the GTN story and to focus on the individual testimonies
and observations from as far back as the late 1860s. Within Alfred Nobel’s dynamite
factories, workers complained of Monday morning headaches, while others suffering from
angina or heart failure noted that chest pain was less severe on working days [31,32]. This
relief from chest pain was explained by GTN’s vasodilatory action, while the Monday
morning headaches uncovered the tolerance issues associated with GTN. The latter led
to workers adding a small amount of GTN to their weekend hats to retain low levels
of GTN exposure when not at work and in so doing, self-medicating to regulate a more
consistent flow of blood to the head. However, headaches linked to GTN are still reported
today, affecting 43% of patients when using 0.2% GTN ointments to reduce the symptoms
of piles [33–35].
These two early observations, when taken alongside those from GTN-treated patients
who complained of alcohol intolerance [21,22,36], represent three crucial and rather sizable
non-lab based pieces in the GTN jigsaw puzzle, which can now be explained, at least
in part, when placed together with the 2002 findings by Chen, Zhang, and Stamler [37].
This work built on studies by others in the 1970s and 1980s, who showed that GTN’s
activity was the result of NO generated in vascular smooth muscle [20,38]. Chen and
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co-workers were able to expand on this by showing that mitochondrial aldehyde dehydro-
genase (MtALDH or ALDH2) was the enzyme through which GTN was bioactivated [37],
despite other enzymatic candidates also being suggested for this role, such as glutathione-S-
transferase [39–43], cytochrome P450 [44–48], and xanthine oxidoreductase [49–55]. Central
to the success of Chen and co-workers findings was the use of mouse RAW264.7 cells,
grown in plentiful quantities, that allowed the identification of 1,2-GDN along with ni-
trite, rather than nitrate, to be confirmed from low, physiologically relevant quantities of
GTN. Following on from the mouse model, the mitochondrial aldehyde dehydrogenase
activity was further confirmed using a bovine liver model and also through comparative
studies using reversible and irreversible ALDH inhibitors such as chloral hydrate and
cyanamide, respectively [37].
11. Aldehyde Dehydrogenase (ALDH)
In hindsight, the alcohol intolerance experienced by GTN patients becomes easy to
explain if GTN functions as both a substrate and an inhibitor for the same enzyme as that
responsible for converting acetaldehyde to acetate, in the second step of ethanol’s metabolic
pathway. In alcohol-related studies conducted between the mid-1980s and 1990s it was
shown that GTN and ISDM, when taken by alcohol-consuming patients, led to nausea,
blurred vision, and other symptoms synonymous with alcohol aversion therapies usually
attributed to disulfiram, which is a known aldehyde dehydrogenase inhibitor [21,22,36,56].
Of the three known human aldehyde dehydrogenase isozymes, one is mitochondrial
(E2 or ALDH2) and two are cytoplasmic (E1, or ALDH1 and E3, or ALDH3). In vitro studies,
including saturation kinetics, involving E1 and E2 have shown that ISDM inactivated both
isozymes by eradicating the enzymes dehydrogenase and esterase activities. ISDM along
with its two hydrolysis products, isosorbide-2-mononitrate (IS2MN) as the minor and
isosorbide-5-mononitrate (IS5MN) as the major product, as confirmed by HPLC, were
all able to covalently inactivate both isozymes of aldehyde dehydrogenase at the active
sites of E1 and E2 [21,22]. Interestingly, the bicyclic isosorbide core of ISDN forms a V-
shaped wedge structure with both an exo- and endo nitrate ester, at the 2 and 5 positions,
respectively (Figure 3). The lower inhibitory binding constants (Ki) for IS2MN and ISDN,
compared to IS5MN, show that the nitrate at the 2-position is most important for recognition
by the enzyme, and these values were also shown to be comparable to GTN when focusing
on the E2 isozyme. However, rate constant data showed that GTN formed covalent
bonds to E2 much faster than either the mono- or di-nitrates, indicating greater reactivity
by GTN [21,22].
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12. The Use of ALDH Inhibitors and ALDH Knockout Models
While the inhibitory effects of ISMN, ISDN, and GTN on ALDH are fascinating, a
discrepancy of sorts was uncovered once vasorelaxation was studied in mouse and rat
models. Using aldehyde dehydrogenase inhibitors, such as daidzin and benomyl [57],
bioactivation of organic nitrates with three or more nitrates, such as GTN, PETN, and
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pentaerythrityl trinitrate (PETriN), were shown to require ALDH2. In contrast, for those
compounds with just one or two nitrates, such as ISDN, pentaerythrityl dinitrate (PEDN),
and pentaerythrityl mononitrate (PEMN), their concentration-relaxation profiles were
unchanged by ALDH inhibitors, suggesting bioactivation was independent of ALDH2
(Figure 4) [58]. This latter observation mirrors the findings of Chen and co-workers (2002),
who did not see ISDN vasorelaxation diminished when using an ALDH2 knockout mouse
model, whereas for GTN at low concentrations (up to 1 micromolar), ALDH2 played a
central role [59]. Using GTN alongside the mono, di, tri, and tetranitrates of pentaerythrityl,
Wenzel and co-workers (2007), using a similar ALDH2-/- mouse model, showed that
the number of nitrates rather than the carbon skeletal core was the dominant feature in
determining which organic nitrates were reliant on ALDH2 for bioactivation [58]. However,
as stated previously, using ALDH1, Pietruszko and co-workers (1995) did identify IS2MN
and IS5MN as key metabolites from ISDN, by TLC and quantitatively by HPLC, which
was reinforced by Tsou (2011) who showed NO release from ISDN due to ALDH1 [60].
This suggests either activity differences between isozymes or the existence of additional
pathways for activation of ISDN that are ALDH independent [21,22]. Interestingly, ALDH3
has also been shown to denitrate GTN, ISDN, and IS2MN [61], while cytosolic ALDH2 has
also been proposed to bioactivate GTN [62], as has ALDH1 [63].
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13. The Active Site of Mitochondrial Aldehyde Dehydrogenase
In the active site of human ALDH2 (or mtALDH2), t ree important cysteine re idues
have been identified [37]. Cys-302 was first identified by Kitson and co-workers (1991)
as an essential nucleophile for attacking aldehyde substrates in the esterase active site of
cytoplasmic aldehyde dehydrogenase from sheep’s liver [64]. Interestingly, in 2009 We zl
and co-workers reported that the ALDH2 mutant lacking Cys-302 showed over a 90% loss
of enzyme activity towards GTN [65]. This is completely understandable since Cys302
is shown to be responsible for the nucleophilic attack preferentially at a terminal nitro
group of GTN to generate thionitrate (RSNO2) and 1, -GDN [37,66]. This accounts for the
production of 1,2-GDN as the dominant metabolite, and, as such, the concentration of this
dinitrate is often used as marker of GTN bioactivation, due to it being inherently more
stable and reliably detectable in comparison to NO, nitrite, nitrate, or peroxynitrite.
Cys301 and Cys303, which sit adjacent to Cys302, provide ideal sites for further
nucleophilic attack, this time through an intramolecular process upon the newly formed
thionitrate, and thus generating disulphide, which inactivates ALDH2 while releasing free
nitrite. Evidence in support of disulphide formation at the active site comes from Shen and
co-workers (2000), who were able to show, using electrospray ionization mass spectrometry,
a 2 amu reduction in the enzyme’s molecular mass (Mr 4821 cf. 4823) when disulfiram was
added to an in vitro model of rat liver mitochondrial ALDH [67]. A reduction in levels of
free thiol groups from this homotetramer enzyme during its inactivation by organic nitrate
was reported by Pietruszko and co-workers (1995) [22], albeit for ALDH1, who showed by
titration with Ellman’s reagent an 80% drop in ALDH1 isozyme activity that was paralleled
with the loss of two enzyme thiol groups.
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Several hypothetical pathways for the denitration of GTN by ALDH2 have been
proposed, resulting in either the generation of free NO or nitrite [5,13–15,20,37,66,68,69].
In 2012, Lang reported a crystal structure for ALDH2 with the thionitrate adduct seen
on Cys302, which is stabilized by two hydrogen bonding interactions, the first with Asn-
169 and the second with Cys302 itself, via the main chain amide [70]. This captures the
product from first reaction step between ALDH2 and GTN, which can be seen in Scheme 1,
alongside two proposals for the subsequent steps, both of which rely on the intramolecular
attack by Cys301 or Cys303 to yield NO while creating the inactivated enzyme, due to
the formation of the inert disulphide. Inactivation by a disulphide bridge via nitration of
the active site was also supported by 14C-labeled ISDN studies (Pietruszko, 1995), which
showed that the organic nitrates carbon skeleton was not bound within the enzyme [22].
In addition, and in support of previous findings, Lang was also able to use different
conformations to support 1,2-GDN as the major metabolite formed in ALDH2′s active site
and furthermore was able to propose the R-enantiomer of 1,2-GDN as the most likely chiral
product formed [70].
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Scheme 1. Two hypothetical pathways for bioactivation (modified from work reported by Chen and Stamler (2006) [66]
and from two of athways proposed by Mayer and Barett (2008) [13]). R = C3H5N2O6.
Other pathways have suggested attack by hydroxide upon the thionitrate, from a
water molecule activated by Glu268 [66]. However, this relies on an intermolecular reaction,
which is likely to be out-competed by the intramolecular alternatives described in Scheme 1.
Furthermore, Wenzl and co-workers (2009) created an ALDH2 mutant lacking Glu-268,
which showed that whilst it is involved in the structural organization of the NAD-binding
pocket it was not equired for the bioactivation of GTN [65]. In addition, a further pathway
describes the formation a sulphenyl nitrite RSONO, followed by O-N homolysis to give
free NO, but this would result in sulphenyl radicals, which upon dimerization would
surely lead to irreversibly inactivated ALDH2, rendering this also as an unlikely route in
the bioactivation of GTN and other nitrates [13].
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Support for the pathway involving metal complexation, as illustrated in Scheme 1, is
especially attractive given the direct reduction to generate NO without the requirement
for any further enzymatic steps. This, clearly, brings into question whether there would
be a sufficient amount of transition metal to fulfil this role. However, the well-known
significance of copper in the NO story, through its already proven ability to catalyze the
release of NO from S-nitrosothiols, via Cu+ and not Cu2+, as established back in the 1990s
(Equation (1)) [25], would surely make this a realistic candidate in this thionitrate chemistry,
especially given its many mitochondrial roles through various copper-dependent proteins,
including those linked to superoxide dismutase and cytochrome c oxidase [71].
The sustained activity of ALDH2 is clearly important for the bioactivation and
metabolism of GTN and other organic nitrates. It has been shown that this activity can
be restored by reductants, such as thiols able to reverse the disulfide bridge forming step
between Cys302 and Cys301/303 (Scheme 1) [37]. Suitable reductants include dithiothre-
itol (DTT) [72,73], mercaptoethanol [22], cysteine, and N-acetylcysteine [12,31], but not
glutathione [66,74]. In addition, ALDH2 can be partially restored by dihydrolipoic acid,
which is a metabolic reductant present in mitochondria [13,74,75].
Returning to the findings by both Chen and Wenzel [58,59], it is feasible to expect
both the number of nitrates on the parent compound, as well as the concentration of
organic nitrate at the active site of ALDH, to be significant in terms of the amount of NO
or nitrite produced. Data from Chen and separately by Wenzel, as already described,
appear somewhat counterintuitive, since the lower nitrated organic nitrates (such as ISDN,
PEMN, and PEDN) were least affected by ALDH inhibitors. The authors speculate that
this somewhat confused picture could be the result of organic nitrates with three or more
nitrates, having an increased likelihood of successfully nitrating one, two, or more cysteines
in the active site of ALDH (such as Cys301, Cys302, and Cys303) thus forming multiple
thionitrates. As a consequence, this may then alter the later mechanistic steps required
for NO or nitrite release in the active site, which could potentially explain, at this point,
the greater and more selective hindrance caused by ALDH inhibitors towards the higher
nitrated compounds such as GTN, PETriN, and PETN.
14. Nitrate Tolerance
Vascular tolerance to GTN occurs if used continuously over 24–48 h [13]. It is for this
reason that GTN patches are removed from patients overnight, with 10–12 h being the
recommended time lapse before being reapplied [76]. While some reports suggest cross
tolerance [66,77], where GTN treatment has been linked to the hindered activity of other
classes of NO-donating compounds, this would seem unlikely as most other NO-donors
release NO by very different mechanisms. However, others have explained this via GTN’s
S-nitrosylation of sGC [78,79]. One problem when comparing GTN behavior with other
NO donors is the lack of detectable free NO from GTN and also the lack of spectroscopic
evidence from GTN to support the formation of the nitrosyl-haem complex, consistent with
NO bound to sGC. The storage of NO in the form of S-nitrosothiols, as a NO congener, may
help explain both of these anomalies, but for those who have instead directly measured
NO levels created by GTN, this has led to some confusion. In 1996, Laursen measured NO
levels created by GTN in both tolerant and control blood vessels and found comparable
levels in each [80]. However, as reported by Mayer and Beretta (2008), instead of this
signifying tolerance downstream of bioactivation, these results should instead be deemed
inconclusive due to such low detectable levels of NO being characteristic across all such
experiments involving GTN. In addition, while the downstream desensitization of sGC has
been linked to GTN, this was only observed at GTN concentrations in excess of therapeutic
levels and after prolonged exposure [13].
Other possible causes of nitrate tolerance include vascular thiol depletion [18,72], which
is plausible based on the requirement of thiols to re-activate ALDH (Scheme 1), and when
considering their central role in non-enzymatic thionitrate pathways (Equations (2)–(4)) and in
the formation of RSNO (Equation (7)). In terms of optimum reactivity between cysteine and
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GTN to form nitrite and inert cystine and thus depleting thiol levels, this is known to occur
most efficiently at pH 9.6, which closely mirrors the pH conditions required by aldehyde
dehydrogenase [31]. For this non-enzymatic thiol chemistry in the mitochondria, this
makes sense, since the thiol group of cysteine and glutathione have pKa values of 8.37 and
8.66, respectively, meaning both will predominantly exist in the ionized, reactive thiolate
form under the pH environments required by mtALDH. Alternatively, such tolerance
could be solely attributed to ALDH2 inactivation, due to disulphide bridging between
Cys302-Cys301/303 in the enzyme’s active site, as already illustrated in Scheme 1.
The final consideration here acknowledges the generation of superoxide as a byprod-
uct of GTN turnover by ALDH2, leading to a build-up of peroxynitrite, which forms the
basis of the oxidative stress hypothesis to explain nitrate tolerance [81–84]. Validation
for this as a cause of nitrate tolerance comes from the detection of superoxide, by hy-
droethidine [65], during GTN’s bioactivation by ALDH2. This is further supported by the
use antioxidants such as vitamin E [85], ascorbate [86], and resveratrol [87], which were
able to reverse tolerance, presumably through the depletion of superoxide, although such
co-administration may also be responsible for both reversing the oxidative inactivation at
ALDH2′s active site and protecting against endothelial dysfunction, as described by Mayer
and Beretta [13]. A product of lipid peroxidation, 4-Hydroxynonenal, has also been linked
with nitrate tolerance in more recent years [88].
15. GTN in Individuals with Lowered Alcohol Tolerance
Lowered alcohol tolerance due to the accumulation of acetaldehyde is seen in around
40% of the East Asian population. It is characterized by the subject flushing following
alcohol consumption, due to the reduction of ALDH2′s dehydrogenase activity and is
caused by a common mutation in the ALDH2 gene, involving a guanine to adenine
polymorphism in exon 12 on chromosome 12. This single point mutation is therefore
responsible for the replacement of glutamate, seen in the wild type, with lysine, as seen in
the mutant, at amino acid position 487 (Glu487Lys) [89]. However, within the literature,
the amino acid nomenclature can appear a little confusing here as the same mutant form
of ALDH2 is also referred to as (Glu504Lys), due to the discovery of 17 additional amino
acids on an N-terminus mitochondrial leader peptide, which were not previously included
in the numbering system [90]. In short, these two descriptions relate to the same mutation
and also explain why active site Cys302 is also reported as Cys319, which, as well as
being the key nucleophilic base in the proposed bioactivation of GTN, is also the essential
nucleophile for the dehydrogenase and esterase activity of the ALDH2 enzyme, which
neatly explains the overlap between GTN bioactivation and alcohol metabolism [90].
In 1983, Goedde and co-workers conducted a study involving 1203 volunteers of
different ethnicity, where the ALDH mutation responsible for alcohol sensitivity was
investigated using skin and hair root samples [91]. Their findings showed clear ethnic
variations. Highland Indians from Ecuador showed the greatest incidence of this ALDH
polymorphism, which was identified in 69% of those studied, whereas in descending
order, for Vietnamese, Japanese, Indonesians, Chinese, and volunteers from northern
Thailand, the figures were 57%, 44%, 39%, 35%, and 8%, respectively. Incidences of
this mutation dropped to zero in the remaining populations studied, which covered
Europeans, Egyptians, Sudanese, Liberians, and Kenyans. Since this alcohol intolerance
mirrors the effects of disulfiram, which is used as an adjunct to out-patient treatment of
alcoholics, lower rates of alcoholism in populations with the Lys504 mutation can be clearly
rationalized, as explained in this study [91].
While Glu504 homozygotes (ALDH2*1/1) have fully functional enzymatic activity, a
drop to negligible levels is seen in Lys504 homozygotes (ALDH2*2/2) and only an uptick
to 6% of normal activity is seen in Glu504/Lys504 heterozygotes (ALDH2*1/2) [92,93].
In light of GTN’s reliance on ALDH2 for bioactivation, as widely reported over the last
20 years, alongside evidence of higher plasma concentrations of GTN in subjects with the
ALDH2 gene polymorphism [94], an obvious question to raise at this point is whether GTN
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therapy is somewhat compromised in subjects carrying the mutant gene. A number of
studies have attempted to answer this with one of the more recent investigations conducted
in Japan, in 2017, which concluded that Lys504 mutant subjects, when administered with
GTN sublingually, showed no difference in terms of vasodilatory effects when compared
to Glu504 wild type subjects [95]. This is reinforced by the findings of He and co-workers
in 2019, following intra-arterial infusion of GTN [96]. In contrast, a Chinese study in
2015, also using sublingual GTN, involving 559 subjects, showed that cardiac output
increased only in wild type subjects, regardless of whether they had coronary heart disease
or not, but these values dropped in mutant subjects both with and without coronary
heart disease, suggesting that GTN intervention may be significantly affected by the gene
polymorphism [97]. In a separate Chinese study also using sublingual GTN, as reported by
Li (2006) [90], for mutant subjects there was a lack of GTN efficacy, which was reinforced
by enzyme kinetic studies that showed a 10-fold drop in GTN metabolism when using
the Lys504 enzyme in place of the ALDH2 wild type. The latter finding maps nicely with
the 10–20-fold drop in nucleophilicity at the active site Cys302/319 due to the presence
of Lys504 [98].
Mackenzie and co-workers (2005) reported enhancements in forearm blood flow, using
intra-arterial administration of GTN, but such improvements were still shown to be 40%
lower in mutant subjects (cf. to wild type) [92]. This was mirrored by wild type responses to
GTN following disulfiram therapy, which were attenuated by 33%, so in effect mimicking
Lys504 mutant behavior, which led Mackenzie and co-workers to conclude that while
important, under half of GTN’s total bioactivation was ALDH2 dependent. This aligns
somewhat with Miura and co-workers’ (2017) description of alternative pathways for GTN
bioactivation, as a way of explaining no vasodilatory differences in their own study [95].
In addition, at a purely molecular level, as a relatively small and flexible molecule with
multiple polar bonds, GTN’s ability to access and either covalently or non-covalently bond
in the active site of other enzymes certainly appears to be a very credible proposition.
Although alternative pathways do appear likely [99–101] and continue to be explored,
the importance of ALDH2 in the bioactivation of organic nitrates cannot be overstated.
Endorsement of this view is exemplified by Zhang and co-workers (2007) who recruited
142 coronary heart disease patients and showed that the amelioration of angina pectoris
attacks within 5 min of GTN treatment was seen in 67.1% of patients who did not show
flushing after drinking wine, compared to just 20.4% in flushing patients. This was
consistent with genotype work, which showed that an efficacious response to GTN in
5 min was seen in 57.5% of Glu504 patients compared to 11.1% in the alcohol intolerant,
Lys504 patients [102].
While reinforcing our understanding of GTN’s bioactivation, these clinical studies
also show that, in addition to asking patients about their weekly alcohol consumption,
healthcare professionals should also explore if their patients are taking any alcohol aversion
therapy or experience any characteristic flushing following an alcoholic beverage [21].
Information on the latter could be viewed as a rather blunt diagnostic tool, but could
actually be extremely useful in an emergency situation given that sublingual GTN is the
standard treatment for acute angina pectoris [103], with others supporting the use of easily
applied GTN patches to provide cardioprotection to at risk patients, during transportation
in ambulances [104].
16. Conclusions
Although some of GTN’s bioactivation will be as a consequence of processes that are
independent of aldehyde dehydrogenase, it is apparent that the active site of this alcohol de-
toxifying enzyme plays a central role in governing the overall efficacy of GTN. It therefore
follows that patients who are able to enjoy an alcoholic beverage without adverse alcoholic
effects, when consumed in moderation, will also be amongst those most likely to experience
the full benefits offered by GTN. That said, 174 years after its first synthesis in Turin, its
complete fate once inside the body remains somewhat puzzling. In addition to other
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plausible enzymatic interventions occurring in tandem with aldehyde dehydrogenase, the
significance of non-enzymatic in vivo reactions following administration of GTN should
not be underestimated. In this regard, many of the remaining queries surrounding GTN
and organic nitrates more generally, appear, at least in part, to resemble those uncovered
whilst pondering in vivo reactions for S-nitrosothiols. As such, the biological cascades for
these two separate classes of NO donor may yet be shown to converge in an even more
complete manner than that already told, as the story of GTN enters the period beyond the
150th anniversary since both its explosive nature and clinical benefits were first realized.
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